Breast Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner
Sheeba Cantanelli, MPAS, PA-C
UT Southwestern Medical Center, Simmons Comprehensive Cancer Center
J Adv Pract Oncol 2021;12(6):576-584 |
© 2021 Harborside™
Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, discusses results from studies evaluating adjuvant therapy with a PARP inhibitor in BRCA-mutated HER2-negative metastatic breast cancer; immunotherapy in the treatment of early-stage triple-negative breast cancer; adjuvant capecitabine after neoadjuvant chemotherapy in triple-negative breast cancer; the addition of palbociclib to fulvestrant in HR-positive, HER2-negative advanced breast cancer; and the impact of vitamin D levels on outcomes. Reporting is provided by The ASCO Post.
For access to the full length article, please sign in